Toward prospective prediction of pharmacokinetics in OATP1B1 genetic variant populations

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 12, 2014, Pages

  Li, R ^a   Barton, H A ^a   Maurer, T S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;

AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; DECISION MAKING; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG CLEARANCE; ENTEROHEPATIC CIRCULATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VITRO STUDY; JAPANESE (PEOPLE); KIDNEY CLEARANCE; LIVER CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84927701275     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.50     Document Type: Article

References (39)

1. The International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-36 (2010).
2. Kalliokoski, A. & Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705 (2009).
3. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011).
4. Generaux, G.T., Bonomo, F.M., Johnson, M. & Doan, K.M. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica. 41, 639-651 (2011).
5. Nies, A.T. et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 5, 1 (2013).
6. Singhvi, S.M., Pan, H.Y., Morrison, R.A. & Willard, D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29, 239-243 (1990).
7. Martin, P.D. et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 25, 2822-2835 (2003).
8. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1∗5, SLCO1B1∗15 and SLCO1B1∗15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005).
9. Tomita, Y., Maeda, K. & Sugiyama, Y. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin. Pharmacol. Ther. 94, 37-51 (2013).
10. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652-662 (2009).
11. Jones, H.M. et al. Mechanistic pharmacokinetic modeling for the prediction of transportermediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab. Dispos. 40, 1007-1017 (2012).
12. Li, R. et al. A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J. Pharmacokinet. Pharmacodyn. 41, 197-209 (2014).
13. Nishizato, Y. et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003).
14. Maeda, K. et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79, 427-439 (2006).
15. Ho, R.H. et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics 17, 647-656 (2007).
16. Niemi, M. et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14, 429-440 (2004).
17. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356-366 (2006).
18. Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726-733 (2007).
19. Tamraz, B. et al. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet. Genomics 23, 355-364 (2013).
20. Mwinyi, J., Johne, A., Bauer, S., Roots, I. & Gerloff, T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004).
21. Choi, J.H., Lee, M.G., Cho, J.Y., Lee, J.E., Kim, K.H. & Park, K. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83, 251-257 (2008).
22. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005).
23. Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T. & Sugiyama, Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm. Drug Dispos. 34, 45-78 (2013).
24. Elsby, R., Hilgendorf, C. & Fenner, K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin. Pharmacol. Ther. 92, 584-598 (2012).
25. Noé, J., Portmann, R., Brun, M.E. & Funk, C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 35, 1308-1314 (2007).
26. Choi, M.K., Shin, H.J., Choi, Y.L., Deng, J.W., Shin, J.G. & Song, I.S. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 41, 24-34 (2011).
27. Deng, J.W. et al. The effect of SLCO1B1∗ 15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1∗15. Pharmacogenet. Genomics 18, 424-433 (2008).
28. Lennernäs, H. & Fager, G. Pharmacodynamics and pharmacokinetics of the HMGCoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403-425 (1997).
29. Rose, R.H., Neuhoff, S., Abduljalil, K., Chetty, M., Rostami-Hodjegan, A. & Jamei, M. Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1- Related Variability in Pharmacodynamics of Rosuvastatin. CPT. Pharmacometrics Syst. Pharmacol. 3, e124 (2014).
30. Hoeper, M.M. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? Eur. Respir. J. 34, 529-530 (2009).
31. Barton, H.A. et al. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin. Drug Metab. Toxicol. 9, 459-472 (2013).
32. Casali, A.M., Siringo, S., Sofia, S., Bolondi, L., Di Febo, G. & Cavalli, G. Quantitative analysis of intrahepatic bile duct component in normal adult human liver and in primary biliary cirrhosis. Pathol. Res. Pract. 190, 201-206 (1994).
33. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993).
34. Kleinstein, S.H., Bottino, D., Georgieva, A., Sarangapani, R. & Scott Lett, G. Nonuniform Sampling for Global Optimization of Kinetic Rate Constants in Biological Pathways. Simulation Conference, 2006 WSC 06 Proceedings of the Winter, Monterey, CA, 3-6 December 2006. 1611-6.
35. Varma, M.V. et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J. Med. Chem. 53, 1098-1108 (2010).
36. Ho, R.H. et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
37. Kitamura, S., Maeda, K., Wang, Y. & Sugiyama, Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 36, 2014-2023 (2008).
38. Pasanen, M.K., Neuvonen, P.J. & Niemi, M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9, 19-33 (2008).
39. Barter, Z.E., Tucker, G.T. & Rowland-Yeo, K. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 52, 1085-1100 (2013).